Literature DB >> 28630236

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.

Noortje Groot1,2, Nienke de Graeff1, Tadej Avcin3, Brigitte Bader-Meunier4, Paul Brogan5, Pavla Dolezalova6, Brian Feldman7, Isabelle Kone-Paut8, Pekka Lahdenne9, Stephen D Marks5, Liza McCann10, Seza Ozen11, Clarissa Pilkington5, Angelo Ravelli12, Annet van Royen-Kerkhof1, Yosef Uziel13, Bas Vastert1, Nico Wulffraat1, Sylvia Kamphuis2, Michael W Beresford10,14.   

Abstract

Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially life-threatening autoimmune disorder with significant associated morbidity. Evidence-based guidelines are sparse and management is often based on clinical expertise. SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise and disseminate management regimens for children and young adults with rheumatic diseases like cSLE. Here, we provide evidence-based recommendations for diagnosis and treatment of cSLE. In view of extent and complexity of cSLE and its various manifestations, recommendations for lupus nephritis and antiphospholipid syndrome will be published separately. Recommendations were generated using the EULAR (European League Against Rheumatism) standard operating procedure. An expert committee consisting of paediatric rheumatologists and representation of paediatric nephrology from across Europe discussed evidence-based recommendations during two consensus meetings. Recommendations were accepted if >80% agreement was reached. A total of 25 recommendations regarding key approaches to diagnosis and treatment of cSLE were made. The recommendations include 11 on diagnosis, 9 on disease monitoring and 5 on general treatment. Topics included: appropriate use of SLE classification criteria, disease activity and damage indices; adequate assessment of autoantibody profiles; secondary macrophage activation syndrome; use of hydroxychloroquine and corticosteroid-sparing regimens; and the importance of addressing poor adherence. Ten recommendations were accepted regarding general diagnostic strategies and treatment indications of neuropsychiatric cSLE. The SHARE recommendations for cSLE and neuropsychiatric manifestations of cSLE have been formulated by an evidence-based consensus process to support uniform, high-quality standards of care for children with cSLE. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Autoantibodies; Corticosteroids; Disease Activity; Systemic Lupus Erythematosus; Treatment

Mesh:

Year:  2017        PMID: 28630236     DOI: 10.1136/annrheumdis-2016-210960

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

1.  The management of lupus in young people.

Authors:  George McGill; Nicola Ambrose
Journal:  Br J Gen Pract       Date:  2018-02       Impact factor: 5.386

Review 2.  Paediatric rheumatology in 2017: Child-centred research is the key to progress.

Authors:  Michael W Beresford; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

3.  Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus.

Authors:  Pondtip Jongvilaikasem; Pornpimol Rianthavorn
Journal:  Eur J Pediatr       Date:  2021-01-03       Impact factor: 3.183

4.  Childhood Systemic Lupus Erythematosus; a Rare Multisystem Disorder: Case Report of a 3-year-old Girl with Oral Involvement as a Primary Sign.

Authors:  Azadeh Horri; Masume Danesh; Maryam Sadat Hashemipour
Journal:  J Dent (Shiraz)       Date:  2020-12

Review 5.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

Review 6.  Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.

Authors:  Jianghong Deng; Nathalie E Chalhoub; Catherine M Sherwin; Caifeng Li; Hermine I Brunner
Journal:  Semin Arthritis Rheum       Date:  2019-03-16       Impact factor: 5.532

7.  Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.

Authors:  Sibel Balci; Rabia Miray Kisla Ekinci; Aysun Karabay Bayazit; Engin Melek; Dilek Dogruel; Derya Ufuk Altintas; Mustafa Yilmaz
Journal:  Clin Rheumatol       Date:  2019-01-16       Impact factor: 2.980

8.  Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov.

Authors:  Yanfang Gao; Yuhan Wang; Rongshan Li; Xiaoshuang Zhou
Journal:  Front Med (Lausanne)       Date:  2021-06-17

9.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

10.  Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity.

Authors:  Mohammed Abd El Monem Teama; Marwa Adham El-Mohamdy; Fatma Abdellah Abdullah Mahmoud; Fatma Mohammed Badr
Journal:  Open Access Rheumatol       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.